Approximately 80% to 90% of patients with bone metastasis from prostate cancer (CaP) will respond to androgen deprivation therapy.1,2 However, the duration of response is finite, averaging 12 to 18 months.3

Combining androgen receptor (AR) antagonists with androgen deprivation therapy has not resulted in a meaningful improvement in survival compared with androgen ablative monotherapy.4,5 Androgen deprivation administered earlier in the course of the disease, for instance prior to the onset of bone disease, has a longer duration of response, but the overwhelming majority of men will still eventually become resistant to this form of therapy.